Alfonso Rodriguez, MD
Hospitalist · Wilkesbarre, PANPI 1598854390
Payments from drug & device makers
Across 58 payments — averaging $19.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$175
- Pfizer$114
- Vifor Pharma, Inc.$109
- OPKO Pharmaceuticals, LLC$96
- Amgen$87
- Sanofi$83
- plus $482 from 17 others
What the payments were for
- Food & beverage$1,146100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 8 | $175 |
| Pfizer | 7 | $114 |
| Vifor Pharma, Inc. | 6 | $109 |
| OPKO Pharmaceuticals, LLC | 6 | $96 |
| Amgen | 4 | $87 |
| Sanofi | 1 | $83 |
| Otsuka America Pharmaceutical, Inc. | 3 | $53 |
| Johnson & Johnson | 3 | $51 |
| AbbVie | 3 | $49 |
| Mallinckrodt Enterprises LLC | 2 | $45 |
| GSK | 2 | $34 |
| Scpharmaceuticals Inc. | 1 | $32 |
| Merck | 2 | $31 |
| Gilead | 1 | $25 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $23 |
| Shire North American Group Inc | 1 | $21 |
| Fresenius USA Marketing, Inc. | 1 | $19 |
| Boston Scientific | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Ultragenyx Pharmaceutical Inc. | 1 | $17 |
| Akebia Therapeutics Inc | 1 | $16 |
| Novartis | 1 | $15 |
| Covidien LP | 1 | $15 |
How this compares
$1,146 in reported general payments places this provider in the 90th percentile of 1,287 hospitalist providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Metoprolol Succinate | 15 | $169 |
| Pantoprazole Sodium | 13 | $73 |
| Furosemide | 12 | $36 |
| Prednisone | 17 | $32 |
Paid to pharmacies, not to this prescriber.
Other hospitalist in Wilkesbarre
- Yaa OppongPhiladelphia$6.8M
- Nader ZakiYork$706K
- Chidiebube EgwimLebanon$224K
- Khalid AhmedPhiladelphia$55K
- Michael SchneiderPhiladelphia$37K
- Umang PatelLanghorne$21K
- Irfan AhsanPhiladelphia$21K
- Kevin VolppPhiladelphia$17K
- Amanulla KhajiWynnewood$15K
- Maria DrosouWynnewood$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.